Merging evidence-based and mechanism-based medicine

The Lancet

Volumn 372, Issue 9638, 2008, Pages 519-520

  van der Wilt, Gert Jan ^a   Zielhuis, Gerhard A ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ARTERIAL CARBON DIOXIDE TENSION; ARTICLE; CLINICAL EFFECTIVENESS; COGNITIVE THERAPY; EVIDENCE BASED MEDICINE; HUMAN; HYPERCAPNIA; HYPERTENSION; HYPERVENTILATION; HYPOCAPNIA; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PRESSORECEPTOR REFLEX; PRIORITY JOURNAL;

EID: 49149117016     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(08)61215-5     Document Type: Note

References (11)

1. National Institute for Health Research. Efficacy and Mechanism Evaluation (EME) programme. http://www.eme.ac.uk (accessed April 30, 2008).
2. Kerr W.J., Dalton J.W., and Gliebe P.A. Some physical phenomena associated with the anxiety states and their relation to hyperventilation. Ann Intern Med 11 (1937) 961-992
3. Feyerabend P. Against method (1988), Verso, London, New York
4. Hibbert G.A., and Pilsbury D. Hyperventilation: is it a cause of panic attacks?. Br J Psychiatry 155 (1989) 805-809
5. Furukawa T.A., Watanabe N., and Churchill R. Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia. Cochrane Database Syst Rev 1 (2007) CD004364.
6. Goldstein D.S. Dysautonomia in Parkinson's disease: neurocardiological abnormalities. Lancet Neurol 2 (2003) 669-676
7. Senard J.-M., Brefel-Courbon C., Rascol O., and Montastruc J.-L. Orthostatic hypotension in patients with Parkinson's disease: pathophysiology and management. Drugs Aging 18 (2001) 495-505
8. Dahlöf B., Devereux R.B., Kjeldsen S.E., et al., for the LIFE study group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359 (2002) 995-1003
9. Brenner B.M., Cooper M.E., de Zeeuw D., et al., for the RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345 (2001) 861-869
10. Redon J. Antihypertensive treatment: should it be treated to blood pressure reduction or to target organ damage regression?. Nephrol Hypertens 14 (2005) 448-452
11. Protogerou A., Papaioannou T., Blacher J., Papamichael C.M., Lekakis J.P., and Safar M.E. Central blood pressures: do we need them in the management of cardiovascular disease? Is it a feasible therapeutic target?. J Hypertens 25 (2007) 265-272